The Medicines and Healthcare products Regulatory Agency (MHRA) Alert – Semaglutide (Wegovy, Ozempic and Rybelsus): Risk of Non arteritic Anterior Ischemic Optic Neuropathy (NAION)
A MHRA has been received about Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Non arteritic Anterior Ischemic Optic Neuropathy (NAION).
Please review the details for MHRA Alert Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Non arteritic Anterior Ischemic Optic Neuropathy (NAION) and the guidance from the College of Optometrist and take any necessary and appropriate actions.
